We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Strabismus and amblyopia. Value of their early detection].
La Semaine des Hôpitaux : Organe Fondé Par L'Association D'enseignement Médical des Hôpitaux de Paris 1983 December 30
The authors emphasize the importance of the relations between strabismus and amblyopia. Strabismus is often the symptom which leads to the discovery of amblyopia. Amblyopia may cause strabismus, as in organic amblyopias induced by congenital lesions of the retina or visual pathways, and visual deprivation amblyopias due to corneal opacities and/or congenital cataracts. Unilateral clouding of normally transparent media (cornea, lens, vitreum) prevents normal stimulation of the retina which is necessary to the development of binocular vision. Anisometropic amblyopias also belong to this category. More often, amblyopia is the consequence of strabismus: it is then termed "functional strabismic amblyopia". Loss of the parallelism of the two visual axes disrupts the functional balance between the images received from the two eyes. The two images are different; one is suppressed. This suppression may eventually lead to amblyopia. Amblyopia was discovered in 593 of 1 757 studied cases of strabismus. Amblyopia was the cause of strabismus in 87 patients and was functional in the remaining 506. Among these latter, visual acuity was inferior or equal to 1/10 in 241 cases and between 2/10 and 7/10 in 265. 147 children in the first group and 136 in the second could be treated. Among these patients, who were treated before the age of seven, complete recovery was obtained in approximately 1/2 of cases and improvement in more than 1/4 of first group patients and 1/3 of second group patients. Results were all the better that treatment was initiated earlier and that patients were younger.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app